Literature DB >> 9190908

IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.

M T Esser1, R D Dinglasan, B Krishnamurthy, C A Gullo, M B Graham, V L Braciale.   

Abstract

IL-2 is a T cell growth factor that has pleiotropic functions in T cell differentiation, induction of lymphokine-activated killer cells, and regulation of immune responses. In studying TCR triggering of perforin or Fas ligand (FasL)/Fas (CD95 ligand/CD95) cytotoxicity in our influenza-specific T cell clones, we found that IL-2 can also induce FasL/Fas cytotoxicity. IL-2 induces FasL/Fas cytotoxicity in our CD8+ and CD4+ Th1 clones, but not in our CD4+ Th2 clones. IL-2 induction of cytolytic activity occurs when the CD8+ T cells are refractory to IL-2-induced proliferation. This killing is Ag independent, MHC unrestricted, and blocked by Fas.Fc fusion protein. IL-2 induces FasL/Fas cytotoxicity in a dose-dependent manner, but does not induce high levels of FasL expression as detected by flow cytometry. TCR triggered FasL/Fas cytotoxicity is detectable in CD8+ and Th1 clones by 3 h and peaks at 6 h; high levels of killing are maintained for at least 24 h. Similarly, IL-2 induces FasL/Fas killing in CD8+ and Th1 clones within 3 h of stimulation and maintains high levels for at least 24 h. TCR-triggered FasL/Fas killing is inhibited by emetine and cyclosporin A, whereas IL-2-induced FasL/Fas killing is inhibited by emetine, but not by cyclosporin A. These results demonstrate a second mechanism to induce FasL/Fas cytotoxicity in CD8+ and Th1 clones and may explain IL-2 induction of Ag-independent MHC-unrestricted lymphokine-activated killer cell activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190908

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

Review 2.  The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM).

Authors:  H T Kreuwel; L A Sherman
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

3.  Protection against polyoma virus-induced tumors is perforin-independent.

Authors:  Anthony M Byers; Annette Hadley; Aron E Lukacher
Journal:  Virology       Date:  2006-09-28       Impact factor: 3.616

4.  Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD).

Authors:  S G Maher; C E M Condron; D J Bouchier-Hayes; D M Toomey
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

5.  Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells.

Authors:  G Z Tau; S N Cowan; J Weisburg; N S Braunstein; P B Rothman
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

6.  Ca2+ signaling modulates cytolytic T lymphocyte effector functions.

Authors:  M T Esser; D M Haverstick; C L Fuller; C A Gullo; V L Braciale
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

7.  Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.

Authors:  S Chidrawar; N Khan; W Wei; A McLarnon; N Smith; L Nayak; P Moss
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 8.  Immunotherapy of brain cancers: the past, the present, and future directions.

Authors:  Lisheng Ge; Neil Hoa; Daniela A Bota; Josephine Natividad; Andrew Howat; Martin R Jadus
Journal:  Clin Dev Immunol       Date:  2011-03-08

Review 9.  Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases.

Authors:  Krittalak Chakrabandhu; Anne-Odile Hueber
Journal:  Front Immunol       Date:  2016-10-17       Impact factor: 7.561

Review 10.  The regulation and maturation of antiviral immune responses.

Authors:  J Lindsay Whitton; Mark K Slifka; Fei Liu; Alexander K Nussbaum; Jason K Whitmire
Journal:  Adv Virus Res       Date:  2004       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.